我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
11 九月 2017, 13:26
3108

Janssen Sciences Announced The Discontimuation of Further Hepatitis C Treatment Development

Janssen Sciences Announced The Discontimuation of Further Hepatitis C Treatment Development - 图片 1

Janssen Sciences Ireland UC (Janssen), of Pharmaceutical Companies of Johnson & Johnson announced that the company would not continue any further hepatitis C treatment development, which was including a combination of three antivirals. The Janssen authorities comment on that it was a strategic decision because of the number of brand new therapy for hepatitis C, and the number increases rapidly.

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally. At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients." - said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen.

作者: Liliya Ten

在社交媒体上分享